Grant ID

97-RC-299-14

Illness

Bipolar Disorder

Primary Drug/Intervention

Pentazocine

Primary Dosage

100 mg

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Completed

Investigator

Murphy

Sample Size

10

Duration of Study Period for Each Subject

16 weeks

Outcome Measurements

Kappa Mania rating scale, the Kappa Mania symptom self-report, the Daily Young Mania Rating Scale

Results

Significant decrease in symptoms of mania one hour after each dose. No adverse effects.

Publication

Cohen BM, Murphy B. The effects of pentazocine, a kappa agonist, in patients with mania. Int J Neuropsychopharmacol 2008;11:243-247.

Link

http://www.ncbi.nlm.nih.gov/pubmed/17897484

PI Name

Beth Murphy

Degree

MD

Center

N/A

Institution

McClean

Address

City or Town

Belmont

State or Province

MA

Zip or Postal Code

N/A

Country

USA

Email Address

murphyb@mcleanpo.mclean.org